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concentrations (Cmin) appears to be a good surrogate to es-
timate AUC24h and to monitor daptomycin treatment in pa-
tients undergoing CRRT.  © 2013 S. Karger AG, Basel
 Introduction
 Daptomycin is a lipopeptide antibiotic with concentra-
tion-dependent bactericidal action against Gram-positive 
organisms including methicillin-resistant  Staphylococcus 
aureus or vancomycin-resistant  Enterococcus  spp.  [1] . 
Daptomycin has a molecular weight of 1,620 daltons, is 
highly protein bound (90–96%) and is mainly eliminated 
by the kidneys. Renal clearance accounts for about 50% of 
total daptomycin clearance. About 30% is presumably 
metabolized in the kidneys and excreted as metabolites 
and only 5% is excreted in the feces  [2] . In  S. aureus blood-
stream infections, including those in patients with right-
sided endocarditis caused by methicillin-resistant and 
methicillin-susceptible strains, the labeled dose is 6 mg/kg 
every 24 h  [3] . As accumulation occurs in patients with 
renal failure, the dosing interval is prolonged to 48 h in 
 Key Words
 Antibiotics · Dosing · Gram-positive infection · Renal
failure · Renal replacement therapy · Intensive care
 Abstract
 Background: The optimal daptomycin dosing regimen for 
critically ill patients undergoing continuous renal replace-
ment therapy (CRRT) has still to be established.  Methods: 
Daptomycin pharmacokinetics was determined in 9 patients 
after administration of 6 mg/kg/day over 5 days.  Results: At 
steady state, which was reached by day 3, the area under the 
curve over 24 h (AUC24h) was 667.4 ± 356.6 mg   ·   h/l, and the 
maximum concentration (Cmax) was 66.9 ±25.3 mg/l. Mean 
CRRT clearance accounted for 48% (range 32–67%) of total 
clearance (mean 10.2 ml/min, range 6.1–18 ml/min). Signifi-
cant correlations were observed between Cmax, minimum 
concentration (Cmin) and AUC24h (R 2  = 0.91, p < 0.001, and 
R 2  = 0.94, p < 0.001) and between albumin plasma concen-
tration and free daptomycin (R 2  = 0.7, p = 0.009).  Conclusion: 
No significant accumulation occurred with a daily daptomy-
cin dose of 6 mg/kg in patients undergoing CRRT with an ef-
fluent flow rate of >30 ml/kg/h. The quantification of trough 
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patients with severe renal insufficiency (creatinine clear-
ance <30 ml/min) or intermittent hemodialysis  [3] . Drug 
dosing guidelines for continuous renal replacement ther-
apy (CRRT) are often not present in the drug’s product 
labeling, and deduction of dosing recommendations from 
intermittent hemodialysis can lead to underdosing  [4] . 
Optimal daptomycin dosing in critically ill patients un-
dergoing CRRT has been a matter of debate in recent 
years. Some authors advocate a dose of 8 mg/kg once every 
48 h  [5, 6] in order to reach sufficiently high peak concen-
trations and to avoid high daptomycin trough concentra-
tions and accumulation. Others found very low plasma 
concentrations at doses of 4 mg/kg every 24 h and recom-
mend a higher dose administered once daily to ensure ef-
ficacy  [5] . Based on a CRRT model with bovine plasma 
showing comparable clearance when compared with nor-
mal renal clearance  [7] , we settled for a once daily regimen 
at our intensive care units at the time. We recently pub-
lished a retrospective chart analysis of 7 critically ill pa-
tients with routinely measured trough and in some cases 
additional peak concentrations  [8] . All of the patients – 
although undergoing CRRT and receiving daptomycin 
doses above 6 mg/kg/day once daily in some cases – had 
daptomycin concentrations below those found in healthy 
volunteers at the equivalent dose  [9, 10] . Therapeutic dap-
tomycin plasma concentrations have not been established 
so far due to lack of clinical data correlating daptomycin 
exposure to outcome in patients with Gram-positive in-
fections. Daptomycin shows rapid concentration-depen-
dent killing in vitro with the area under the curve (AUC) 
over 24 h (AUC24h)/minimal inhibitory concentration 
(MIC) ratio and peak concentration (Cmax)/MIC ratio 
being the main determinants of the bactericidal effect  [11, 
12] . Based on these in vitro results, the European Commit-
tee on Antimicrobial Susceptibility Testing suggests a 
mean AUC24h/MIC target of 438 of total drug for a bac-
teriostatic effect against susceptible  S. aureus strains (MIC 
 ≤ 0.5 mg/l), and for a bactericidal effect, a mean AUC24h/
MIC target of 1,061 is recommended  [11, 13] . This expo-
sure would theoretically translate into a minimal AUC0–
24h of 400 mg    ·     h/l for a bactericidal effect, which is at-
tained with a dose of 6 mg/kg in healthy volunteers  [9, 10] . 
Nevertheless, in severely ill patients with fever in neutro-
penia and in patients with burn injury considerably lower 
daptomycin exposure was observed  [14, 15] . The aim of 
this prospective pharmacokinetic (PK) study was to deter-
mine the PK of daptomycin administered once daily at a 
dose of 6 mg/kg in patients undergoing CRRT and to con-
firm that no significant accumulation occurs with this 
dosing regimen and that sufficient drug exposure is 
achieved. Additionally, we investigated the value of Cmax 
and minimum concentration (Cmin) for monitoring dap-
tomycin exposure.
 Materials and Methods
 Study Design and Study Population
 This prospective PK study was performed in two intensive care 
units of the University Hospital Zurich, Switzerland. Nine criti-
cally ill patients undergoing CRRT because of anuric renal failure 
who had commenced first-line antibiotic treatment for proven or 
suspected Gram-positive infection were included. Daptomycin 
was administered additionally only for study purposes over 5 days. 
Patients were not included if they had creatinine phosphokinase 
(CPK) concentrations >2 times the upper normal range, severe 
liver function impairment (Child class C) or a life expectancy of 
less than 5 days. If the patient was unable to sign the informed con-
sent, a next of kin and an independent physician had to confirm 
the presumed will of the patient to participate in the study. The 
patient was asked for informed consent as soon as he/she regained 
cognitive functions. Physical examination and laboratory evalua-
tion were performed daily to identify adverse drug effects. In the 
case of CPK elevation >5 times the upper limit of normal, treat-
ment with daptomycin was stopped. The study (NCT01212432, 
ClinicalTrials.gov) was approved by the local ethics committee and 
Swissmedic, the Swiss national regulatory agency. Independent 
monitoring of protocol adherence was ensured by the Clinical Tri-
al Center at the University Hospital Zurich.
 CRRT Procedures
 Continuous venovenous hemodiafiltration (CVVHDF) or 
continuous venovenous hemodialysis (CVVHD) were performed 
with Multifiltrate (Fresenius Medical Care, Homburg, Germany) 
using the capillary hemofilter AV 1000s (polysulfone, surface area 
1.8 m 2 ) or with Prismaflex ST150 (Gambro AB, Lund, Sweden) us-
ing the capillary hemofilter AN69 ST (acrylonitrile-sodium-meth-
yl sulfonate, surface area 1.5 m 2 ). The total combined filtration and 
dialysate rates were maintained between 30 and 40 ml/kg/h if pos-
sible. Substitute solutions were usually supplied after the filter, un-
less repeated clotting made prefilter substitution necessary. The 
blood flow rate was set between 100 and 200 ml/min. 
 Drug Administration
 Daptomycin (Cubicin ® ; Novartis, Basel, Switzerland) was di-
luted in 0.9% sodium chloride and administered intravenously at 
a dose of 6 mg/kg over 30 min. The drug was given every 24 h on 
5 consecutive days.
 Sampling and PK Assessments
 Extended PK sampling was performed on days 1 and 3. On 
these days, daptomycin concentrations were determined in arte-
rial blood before daptomycin infusion (Cmin) as well as 0.5 (end 
of infusion, Cmax), 1, 2, 4, 8, 12 and 24 h after the start of drug 
administration. Additional samples were taken before and after 
the filter as well as from the ultrafiltrate twice during these days. 
Daptomycin concentration was also measured in the urine, which 
was, if available at all, collected over 24 h. On day 5, only arterial 
blood samples were taken, 0.5 (Cmax) and 24 h (Cmin) after dap-
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tomycin infusion. The unbound fraction and free daptomycin 
concentration were determined in all available peripheral arterial 
blood samples on day 3. Samples were analyzed by liquid chroma-
tography tandem mass spectrometry using a C18 reversed-phase 
analytical column, 0.1% formic acid and methanol as the mobile 
phase and electrospray ionization. Heparinized plasma samples 
were extracted by protein precipitation after the addition of the 
internal standard (CB 183253). The concentration of daptomycin 
was calculated by linear regression analysis of the calibration curve 
ranging from 0.1 to 150 mg/l. The lower limit of quantification of 
the method was 0.03 mg/l, the precision 3.1% and the accuracy 
101%. Unbound daptomycin was estimated by ultrafiltration of 
plasma using Millipore Centrifugal Filter Units (Merck Millipore, 
Billerica, Mass., USA). The units were centrifuged for 30 min at 
1,000  g and 25   °   C. An aliquot of the ultrafiltrate was prepared as 
described above and analyzed by liquid chromatography tandem 
mass spectrometry.
 Results are shown as arithmetic means ± standard deviation un-
less otherwise stated, and p values <0.05 are considered significant. 
PK parameters were calculated for both total and free daptomycin 
using standard noncompartmental approaches (WinNonlin 5.3; 
Pharsight Corp., Mountain View, Calif., USA). Missing trough lev-
el data points (Cmin) were estimated by extrapolation using the 
logarithmic plasma concentrations at the last 2 time points with 
quantifiable concentrations. AUC was calculated using the linear 
trapezoidal rule. Cmax and Cmin concentrations were taken di-
rectly from the raw data. Total clearance was calculated as dose/ 
AUC at steady state (AUCss). The terminal elimination rate con-
stant (z) was estimated from the slope of the terminal (exponential) 
phase of the logarithmic plasma concentration-time profile using 
at least 3 data points. The elimination half-life was determined as 
0.693/z. The comparison of PK parameters on days 3 and 5 to base-
line values was done using linear mixed effect modeling. Geometric 
mean ratios and 90% confidence intervals around these ratios were 
calculated on ln-transformed parameters. No significant difference 
from baseline was accepted as present if the confidence interval was 
entirely within the 0.8–1.25 bioequivalence zone. The effect of 
CRRT on daptomycin clearance (Cl CRRT ) was evaluated after mea-
surement of the daptomycin concentration in the venous prefilter 
blood (Cpre), the venous postfilter blood (Cpost) and the ultrafil-
tration fluid (Cuf). In cases where CVVHDF was performed in 
predilution mode, Cl CRRTpre  of the prefilter portion was corrected 
by the dilution factor D and then added to the postfilter and dialy-
sis portion (Cl CRRTpost + dial ). The sieving coefficient (SC), saturation 
coefficient and Cl CRRT  were determined by the following equations 
 [16] :
 SC (saturation coefficient) = 2 × Cuf/(Cpre + Cpost); 
 Q ufd  = sum of ultrafiltrate and dialysate flow rate (Q uf  + Q d );
 Q ufpre  = predilution ultrafiltrate flow rate;
 D = blood flow rate/(blood flow rate + replacement fluid rate);
 Cl CRRTpre  = D × SC × Q ufpre       
 Cl CRRTpost + dial  = SC × Q ufpost + d 
 Cl CRRT  = Cl CRRTpre  + Cl CRRTpost + dial 
 Table 1.  Patient characteristics
 Patient 
No. 
 Age,
 years 
 Gen-
 der 
 Weight,
 kg 
 BMI  Diagnosis  Albu-
 min,
 g/l 
 Daily
 dapto-
 mycin
 dose,
 mg 
 CRRT
 machine/
 mode/
 substitution 
 Mean
 CRRT
 effluent
 flow,
 ml/kg/h 
 Mean daily
 CRRT
 effluent
 flow on
 days 1/3/5, 
liters/h 
 CRRT 
SC a 
 Cl CRRT a , 
ml/min 
 1  80  M 82  32.1  cardiogenic shock,
 chronic renal failure 
 26  500  MF/CVVHDF/post  36.9  2.8/2.7/3.6  0.08  3.5 
 2  64  M 63  21.8  CMV pneumonitis   18  390  MF/CVVHDF/pre  33.8  2.1/2.1/2.2  0.14  3.6 
 3  70  M  117  36.1  septic shock  20  700  MF/CVVHDF/pre  31.9  4.0/3.6/3.6  0.15  5.7 
 4 b  72  M 95  29  septic shock  31  570  MF/CVVHDF/pre  36.8  3.5/–/–  0.11  3.0 
 5  66  F 70  25.7  sepsis  18  420  PF/CVVHDF/post  32.8  2.1/2.4/2.4  0.16  6.1 
 6  63  F 42  19.8  renal transplant,
 intra-abdominal abscess 
 18  250  MF/CVVHD  69.8  2.2./2.4/2.4  0.16 c  6.1 
 7  66  F  120  45.2  septic shock,
 multiorgan failure 
 26  700  PF/CVVHDF/post  24.4  4.2/2.4/2.2  0.06  3.8 
 8  71  M 75  26.2  septic shock,
 endocarditis 
 21  450  MF/CVVHDF/
 post/pre 
 29.3  2.2/2.2./2.2  0.11  2.5 
 9  64  M 85   25.3  hemorrhagic shock,
 liver disease 
 20  500  MF/CVVHDF/pre  34.5  2.5/3.3/3.0  0.24  6.7 
 Mean
± SD 
 68.4
±5.4 
 83
±26 
 29
±7.8 
 22
±4.6 
 497.7
±145.1 
 36.7
±13 
 2.7
±0.6 
 0.13
±0.05 
 4.5
±1.5 
 BMI = Body mass index; CMV = cytomegalovirus; MF = multifiltrate; PF = Prismaflex; post = postdilution; pre = predilution.
 a  Values from day 3.  b  Died on study day 2 for reasons unrelated to the study.  c  Saturation coefficient. 
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 Fig. 1. Individual plasma concen-
tration-time curves of total dapto-
mycin in 9 critically ill patients un-
dergoing CRRT. Day 1: open cir-
cles; day 3: shaded circles; day 5: 
closed triangles. 
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 Results
 Subject Demographics
 Baseline characteristics and individual clearance re-
sults of the 9 patients are shown in  table 1 . Eight patients 
completed the study, and 1 patient died on the second 
study day for reasons unrelated to the study. Therefore, 
PK data of the third and fifth days are missing for this pa-
tient. The total daily daptomycin dose ranged from 250 
to 700 mg (mean 497 ± 145 mg). All patients were anuric 
(<50 ml of urine per day) during the study period; there-
fore, no renal clearance was determined. In 8 patients, 
CVVHDF was used with predilution in 4 patients, and in 
1 patient, CVVHD was performed. 
 PK Results
 PK parameters are presented in  table  2 . Individual 
plasma concentration-time curves are shown in  figure 1 . 
No accumulation between day 1 and day 3 (AUC24h) and 
no further accumulation from the third to the fifth treat-
ment day (Cmax and Cmin) occurred. The 90% confi-
dence intervals of Cmax and AUC geometric mean ratios 
were not outside the bioequivalence zone of 0.8–1.25. 
Cl CRRT  varied by up to 2.7-fold between patients, ranging 
from 2.5 to 6.7 ml/min (mean 4.5 ml/min). Mean CRRT 
clearance accounted for 48% (range 32–67%) of total dap-
tomycin body clearance (mean 10.2 ml/min, range 6.1–18 
ml/min).
 Table 2.  PK parameters
 Day 1  Day 3  Day 5 
 mean ± SD  GM  mean ± SD  GM  GM ratio
 day 3/day 1 
 90% CI of 
GM ratio 
 me an ± SD  GM  GM ratio 
day 5/day 3 
 90% CI of 
GM ratio 
 Cmax, mg/l  65.8  ±  17.1  63.5 (30.5) 77.2  ±  31.3 72.1 (40.8)  1.13  0.83  –  1.54  66.9  ±  25.3  62.2 (44.1)  0.86  0.62  –  1.18 
 Cmin, mg/l 7.7  ±  4.1 6.8 (64.1) 13.1  ±8.3 10.7 (81.1)  1.58  0.86  –  2.9  15.6  ±  11.1  11.9 (106.2)  1.1  0.59  –  2.06 
 AUC a , mg∙h/l 611  ±  286 548 (55)  667.4  ±  367.6  588.2 (57.6)  1.07  0.70  –  1.65 
 FU, % 22  ±  8 
 fAUC24h, mg∙h/l  131.3  ±  43 
 fCmax, mg/l 15.7  ±  4.9 
 T 1/2 , h  10.6  ±  2.4  10.3 (23.1) 12.5  ±  2.3 12.3 (20.8) 
 Total clearance, 
 ml/min 
10.5±  4 13.2 (32.3) 
 Values in parentheses represent coefficients of variation. CI = Confidence interval; FU = fraction unbound; GM = geometric mean; fAUC = AUC of free 
daptomycin; fCmax = free Cmax; T 1/2 = half-life .  a  Day 1: AUCinfinity; day 3: AUC24h. 
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 Fig. 2. Individual total daptomycin AUC24h correlated to individual Cmax ( a ) and Cmin ( b ). 
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 We observed a highly significant linear correlation
between daptomycin peak concentrations and AUC24h 
(R 2  = 0.91, p < 0.001) and between Cmin and AUC24h
(R 2  = 0.94, p < 0.001;  fig. 2 a, b). A negative linear correla-
tion of the calculated SC (R 2  = 0.51, p = 0.046) and the free 
fraction to albumin (R 2  = 0.71, p = 0.009) was observed 
( fig. 3 a). Patients with the lowest albumin plasma concen-
trations (18 g/l) had the highest free daptomycin fraction 
in plasma (24–34%), while in patients with albumin plas-
ma concentrations of 26 g/l, the unbound fraction ranged 
from 8.4 to 16.3%. A certain negative correlation was seen 
with albumin plasma concentrations and Cl CRRT  (R 2  = 
0.35, p = 0.006;  fig. 3 b).
 Safety
 One potential-drug related adverse event occurred. One 
patient with pre-existing liver disease had a transient increase 
of liver enzymes and international normalized ratio on the 
last study day. He transiently required higher vasopressor 
doses but stabilized in the consecutive days. No drug-related 
CPK elevation was recorded in any of the patients.
 Table 3.  Overview of published daptomycin PK data in CRRT and dosing recommendations
 Author
 (number
of patients) 
 Dosing and 
 timing of PK 
 CRRT mode
 (filter type/
 surface) 
 Q ufd, 
 liters/h 
 SC  FU,
% 
 Cl CRRT,
 ml/
 min 
 Cl tot, 
 ml/
 min 
 Cmax,
 mg/l 
 Cmin,
 mg/l 
 AUC48h, 
 mg∙h/l 
 AUC24h,
 mg∙h/l 
 AUC24– 
 48h,
 mg∙h/l 
 Dosing
 recommenda-
tion in CRRT 
 Vilay et al.
 [18] (8) 
 8 mg/kg/48 h SD
 4 mg/kg/24 h a 
 CVVHD
 (Optiflux 
F160NR/1.5 m 2 ) 
 2.6  ±  0.3  0.15   0.17  6.3   11.3  81  ±  19 a 
 52  ±  12 a 
7  ±  5 a 
 12  ±  5 a 
 1,060  ±  301 a 
 1,052  ±  292 a 
 8 mg/kg/48 h 
 Khadzhynov
et al. [5] (8)  
 8 mg/kg/48 h SD
 4 mg/kg/48 h MD 
 CVVHD
 (Fresenius
 PF140 h/1.4 m 2 ) 
 2.0  n.d.  n.d.  8.3  11  87.5  ±  15
41  ±  5 
5  ±  2.6
 2.5  ±  1 
 899  ±  268
 468  ±  84 
 537  ±  97
 302  ±  3 
 193  ±  69
 102  ±  24 
 >4 mg/kg/24 h 
 Wenisch
 et al. [6] (9) 
 6 mg/kg/24 h 
 PK day 1/day 3 
 CVVHDF
 (Prismaflex 
M100/0.9 m 2 ) 
 2.0  0.15  0.16  n.d.  6.9  62  ±  16
 78  ±  22  
 14  ±  6
 22  ±  14 
 555  ±  94    8 mg/kg/48 h 
 Falcone et al.
 [23] (6) 
 6 mg/kg/24 h
 8 mg/kg/24 h
 6 mg/kg/48 h
 8 mg/kg/48 h
 timing n.d. 
 CVVHDF
 (n.r.) c
 CVVHD
 (n.r.) 
 n.d.  n.d.  n.d.  n.d.  12/17 b 
9 b 
6 b 
 10/9 b 
44/37 b 
61 b 
55 b 
 109/61 b 
 
 512 b 
 556/607 b 
 158/193 b 
 566 b 
 6 mg/kg/24 h
 (CVVHDF)
 6 mg/kg/48 h
 (CVVHD) 
 Cl tot  = Total clearance; SD = single dose; MD = multiple dose; n.d. = not determined; n.r. = not reported.
 a  Simulated data at steady state.  b  Individual patient values.  c  Gambro SepteX in 1 patient with 6 mg/kg/24 h multiple dose. 
R2 = 0.71
M
ea
n 
FU
 d
ay
 3
 (%
)
10
Albumin (g/l)
1816
15
20
25
30
35
2220 2624 28
a
In
di
vi
du
al
 m
ea
n 
Cl
CR
RT
 d
ay
 3
 (m
l/m
in
)
2
Albumin (g/l)
R2 = 0.355
201816
3
4
5
6
7
22 2624 28 3230
b
 Fig. 3. Individual mean free daptomycin fraction (FU;  a ) and Cl CRRT  ( b ) correlated to individual plasma albumin on study day 3. 
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 Discussion
 In this study, we investigated the PK of once daily dap-
tomycin at a dose of 6 mg/kg over a period of 5 days in 8 
patients treated with CVVHDF and 1 patient undergoing 
CVVHD. We found that no significant drug accumu-
lation occurred over the study period, and daptomycin 
exposure at steady state was similar to values found in 
healthy volunteers with 6 mg/kg/day. Transmembrane 
clearance of daptomycin in CVVHDF (mean 4.4 ml/min) 
and CVVHD (6.1 ml/min) was only minimally below
renal clearance in subjects with normal renal function 
(6.5 ml/min)  [2] , suggesting a sufficient elimination by 
CVVHDF and also CVVHD. In a CRRT model study 
with bovine plasma, lower daptomycin clearance values 
were found in CVVHD compared to continuous hemo-
filtration at flow rates usually used in clinical practice of 
2–3 liters/h (5–8 vs. 7–10 ml/min). The main factors in-
fluencing clearance were filter surface and ultrafiltrate 
and dialysate flow rates  [7] . In addition, drug clearance 
is significantly reduced in continuous hemofiltration 
by prefilter fluid replacement  [17] . This might in part 
 explain similar CRRT clearance values found with 
 CVVHDF in predilution mode compared to CVVHD in 
our patients. However, definitive conclusions on differ-
ences in drug removal efficiency between the two tech-
niques cannot be drawn due to low patient numbers.
 Total clearance at steady state in our patients (10.6 
ml/min with CVVHDF and 13.4 ml/min with CVVHD) 
was in the range of clearance values found in healthy 
subjects (6.1 and 13.3 ml/min)  [9, 10] . The proportion 
of daptomycin excreted by CRRT versus total clearance 
was also comparable to renal clearance versus total 
clearance measured in healthy volunteers (48 vs. 50%) 
 [2] . Mean AUCss on the third day (667 mg      ·      h/l) was 
within the range of values measured in healthy volun-
teers with the equivalent dose administered at steady 
state (747 and 632 mg     ·      h/l)  [9, 10] . In contrast, mean 
Cmax was substantially lower on days 3 and 5 (77.2 and 
66.9 mg/l) compared to healthy volunteers (98.6 and 
93.9 mg/l)  [9, 10] and even lower on the first day (65.8 
mg/l). A possible explanation might be a higher volume 
of distribution in critically ill patients with renal failure 
in consequence of decreased protein binding and fluid 
overload  [4] . The free daptomycin fraction in our pa-
tients (22 ± 8%) was higher than values reported by 
Wenisch et al.  [6] and Vilay et al.  [18] (16 and 17%, re-
spectively) and more than twice as high as in healthy 
volunteers (4–10%)  [10] . The free fraction correlated 
significantly with albumin plasma levels ( fig. 3 a), and a 
weak correlation of CRRT clearance with albumin 
( fig. 3 b) was found. In consequence, a higher free dap-
tomycin fraction in critically ill patients might add to the 
relatively high clearance in CRRT. 
 Daptomycin exposure showed high variability in our 
patient population. The lowest AUC24h values were 265 
mg    ·    h/l (patient 6) and 389 mg    ·    h/l (patient 9), probably 
due to very low total daily doses and relatively high filtra-
tion rates relative to body weight. Both patients did not 
even meet the bacteriostatic target of AUC24h/MIC >438 
recommended by the European Committee on Antimi-
crobial Susceptibility Testing assuming an MIC of 1 mg/l. 
Insufficient exposure to daptomycin can lead to treat-
ment failure  [19] and bears the risk of selection of resis-
tant strains. Furthermore, daptomycin exhibits lower po-
tency against  Enterococcus spp., with up to 4-fold higher 
MICs compared to  S. aureus  [13] . More than doubling of 
the daptomycin dose was necessary to reach 50% of the 
maximum effect against  Enterococcus faecium  compared 
to  S. aureus in an in vitro pharmacodynamic model  [20] . 
Total drug concentrations measured in our study could 
therefore theoretically be insufficient to treat  Enterococ-
cus spp. On the other hand, the relatively high free frac-
tion of daptomycin in critically ill patients might partial-
ly overcome the lower total drug exposure. A free AUC/
MIC ratio of >40 was associated with bactericidal activity 
and a minimum risk of emergence of resistance in meth-
icillin-resistant  S. aureus and vancomycin-resistant  S. au-
reus strains  [21] . In our patients, a free daptomycin AUC/
MIC of  63–400 could be calculated for  S. aureus strains 
with an assumptive MIC of 0.5–1 mg/l. Whether this ex-
posure would be sufficient for the treatment of  Enterococ-
cus spp. is not known. 
 Steady state was reached on the first treatment day in 
most of the patients. Only in patients 3 and 7 an AUC in-
crease by 1.4- and 1.7-fold from day 1 to day 3 was ob-
served. The lower exposure on the first PK measurement 
day coincided with high effluent rates of 4 and 4.2 liters/h, 
respectively, with a subsequent decrease to 3.6 and 2.4 
liters/h on the following PK measurement day. Converse-
ly, in patient 9, the effluent rate was increased on the sec-
ond day with a decrease in daptomycin exposure indicat-
ing an influence of ultrafiltration rates on daptomycin 
elimination. Minimal accumulation was observed in the 
remaining patients who had a constant CRRT filtration 
rate over the study period. 
 One study reporting PK in extended hemodialysis 
(ED)  [22] and 4 studies investigating the PK of dapto-
mycin in patients undergoing CRRT ( table 3 )  [5, 6, 18, 
23] have been published so far. Efficient elimination of 
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23% daptomycin in ED over 8 h with high-flux filters 
was found, leading to the conclusion that once daily 
dosing is appropriate for patients undergoing ED. In 
the 12 patients undergoing CVVHDF reported by 
Wenisch et al.  [6] and Falcone et al.  [23] , daptomycin 
was administered at a dose of 6 mg/kg every 24 h in 11 
patients and 8 mg/kg every 24 h in 1 patient. Wenisch 
et al.  [6] determined PK during the first 3 days in 9 pa-
tients. An accumulation of daptomycin from the first to 
the third day by 19% (Cmax) and 60% (Cmin), similar 
to our findings of 13% (Cmax) and 58% (Cmin), was 
observed. Mean AUC24h on the third day was still be-
low our AUCss value (555 vs. 667 mg    ·    h/l). In contrast 
to our study, they did not determine daptomycin plas-
ma concentrations on the subsequent days. Based on an 
additional dosing simulation with a dose of 8 mg/kg 
every 48 h, the authors suggest that a dose of 8 mg/kg 
every 48 h would be appropriate to avoid accumulation 
and high trough levels. Even lower AUC24h values were 
found by Falcone et al.  [23] in the 2 patients receiving
6 mg/kg every 24h (158 and 193 mg    ·    h/l). The very low 
exposure was attributed to the use of a high cutoff filter 
in 1 patient, but in none of the patients timing of sam-
pling, ultrafiltration rates or clearance values were re-
ported. In the patient who had received 8 mg/kg dapto-
mycin every 24 h, AUC24h was 566 mg    ·    h/l. Neverthe-
less, the authors suggest that 6 mg/kg every 24 h is the 
optimal dose in CVVHDF. 
 In the studies using CVVHD  [5, 18, 22] , daptomycin 
was administered every 48 h to all of the 18 patients re-
ported. While CVVHD settings in the studies of Vilay et 
al.  [18] and Khadzhynov et al.  [5] were comparable to 
our settings, again no information on this issue is pro-
vided by Falcone et al.  [23] . Vilay et al.  [18] determined 
single-dose PK over 48 h and simulated steady-state PK 
for dosing of 8 mg/kg every 48 h and 4 mg/kg every
24 h. Simulated AUC48h values were similar for the two 
dosing regimens. The authors conclude that daptomy-
cin dosing of 8 mg/kg every 48 h would be more appro-
priate in patients undergoing CVVHD in order to reach 
sufficient peak concentrations and avoid trough levels 
above 20 mg/l, although only 1 patient had a simulated 
Cmin at steady state of >20 mg/l. Falcone et al.  [23] rec-
ommend dosing of 6 mg/kg every 48 h based on the fact 
that AUC48h values in the CVVHD patients were simi-
lar to AUC24h values in their CVVHDF patients who 
received daptomycin at 6 mg/kg every 24 h. However, 
AUC48h should be twice as high as AUC24h for a simi-
lar AUC over 48 h. Hence, a very low daptomycin expo-
sure, especially on the second day, must be assumed. 
The low AUC48h indicates that even in CVVHD pa-
tients, a once daily dosing of 6 mg/kg might have been 
appropriate, provided that similar CVVHD settings 
were used. In fact, Khadzhynov et al.  [5] recommend 
once daily dosing of at least 4 mg/kg based on very low 
daptomycin exposure over 24–48 h in the 8 CVVHD 
patients studied with a dosing interval of 48 h.
 Despite the fact that higher Cmax is reached with dos-
es of 8 mg/kg, we think that this advantage has to be bal-
anced against the risk of loss of bactericidal effect when 
the dosing interval is extended from 24 to 48 h  [24] . Our 
data strongly support the recommendation made by 
Khadzhynov et al.  [5] and confirm that once daily dosing 
of 6 mg/kg is necessary to achieve adequate daily dap-
tomycin concentrations without a risk of overdose in
patients undergoing CVVHDF and probably also in
CVVHD with comparable hemodialysis rates. Particular-
ly in critically ill patients with often severe Gram-positive 
infections, higher daptomycin exposure might be more 
favorable as the drug exhibits a concentration-dependent 
antimicrobial effect. 
 Close correlations of Cmax and Cmin with AUC24h 
were observed ( fig. 2 ). Measurement of AUC by extensive 
PK sampling is time-consuming, expensive and error 
prone in clinical routine; therefore, monitoring of Cmax 
or Cmin might be a valuable alternative to estimate AUC 
and to ensure adequate daptomycin exposure in critically 
ill patients undergoing CRRT. Since, in contrast to other 
studies in critically ill patients, we intensively collected 
samples for daptomycin quantification on the first 5 
treatment days, our results robustly show the usefulness 
of Cmax and Cmin quantification for AUC24h estima-
tion.
 A shortcoming of our study is the small number of 
participants, which translated into large 90% confidence 
intervals and reflects the large variability in daptomycin 
PK. However, recruitment of critically ill patients in an 
intensive care unit is difficult, as confirmed by the low 
number of participants in other studies on comparable 
populations.
 Conclusion
 In conclusion, daptomycin PK in patients undergoing 
CVVHDF or CVVHD at rates of 30–40 ml/kg/h were 
comparable to those in healthy volunteers. We showed 
that no further accumulation occurred after the third 
treatment day with once daily dosing. Hence, we suggest 
at least 6 mg/kg daptomycin once daily should be given 
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to critically ill patients undergoing CVVHDF and most 
probably also in CVVHD. Monitoring of daptomycin 
concentrations seems advisable in view of the variability 
in drug clearance and daptomycin plasma concentrations 
in patients undergoing CRRT. The quantification of 
trough concentrations (Cmin) appears to be a good sur-
rogate to estimate AUC24h values. However, therapeutic 
ranges remain to be established and validated in future 
studies.
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